98%
921
2 minutes
20
Highlights: There is a concern that agricultural producers could be misusing opioids to cope with stress and injuries. Focus groups were held in Mississippi to determine perceptions of opioid misuse in the agricultural community. Results found that alcohol misuse, not opioid misuse, is an issue for Mississippi agricultural producers. Focus group participants believe that other groups in their communities have issues with opioid misuse.
Abstract: Opioid misuse has been identified as a concern among the farming community. The aim of this study is to identify how opioid misuse is perceived in agricultural communities across the state of Mississippi. A series of focus groups were conducted with University Agricultural and Natural Resource Extension agents and agricultural producers in Mississippi between November 2020 and February 2021. Focus group transcripts were analyzed through thematic analysis. Both university Extension agents and agriculture producers believe that opioid misuse is more of a concern in the greater rural community, amongst younger individuals, as opposed to being a concern for producers themselves. Extension agents stated that the unique personalities of agricultural producers might prevent them from being upfront about any of their opioid misuse. Agricultural producers stated that alcohol misuse is more of a concern among their peers than opioid misuse and that opioid misuse is present in farm labor. Generally, the focus groups revealed that participants did not think that opioid misuse was an issue for agricultural producers in Mississippi. However, participants identified other groups in their communities as having issues with opioids. The private nature of agricultural producers could be a reason why opioid misuse is not perceived to be widespread in that group. Alcohol misuse was observed as an issue for agricultural producers in the producer focus groups.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.13031/jash.15250 | DOI Listing |
Cochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDFSubst Use Addctn J
October 2025
Partnered Evidence-based Policy Resource Center, Boston VA Healthcare System, Boston, MA, USA.
Objectives: To estimate the effect of the passage of state laws targeting patient brokering on opioid-related outcomes.
Background: In response to growing awareness of unethical substance use disorder (SUD) treatment practices, several states in the United States have passed laws targeting patient brokering and deceptive marketing. Patient brokering and deceptive marketing laws are intended to reduce the chances individuals with SUD interact with bad actors or suffer from adverse outcomes related to inappropriate SUD treatment, but the effectiveness of these laws is unknown.
Subst Use Addctn J
October 2025
Health Economics Resource Center, VA Palo Alto Health Care System, Palo Alto, CA, USA.
Background: To address the opioid use disorder (OUD) public health crisis, the ADvancing Pharmacological Treatments for OUD (ADaPT-OUD) external facilitation randomized trial was conducted in 8 intervention and 27 matched control low-performing Veterans Health Administration (VHA) facilities to increase the prescribing of medications for OUD (MOUD). Facilities were considered low-performers if they were in the bottom quartile of the facility ratio of Veterans with OUD who received MOUD. The objective of this analysis was to evaluate the healthcare expenditures of Veterans with OUD who received care in ADaPT-OUD intervention facilities compared to those receiving care in matched control facilities.
View Article and Find Full Text PDFBMJ Open
September 2025
Faillace Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA.
Introduction: Exposure to prescription opioids following traumatic injury can increase the risk of developing tolerance, persistent opioid use and opioid use disorder. The mechanisms underlying opioid tolerance or dependence are not well understood, and no biomarkers predict risk. Opioid exposure causes epigenetic modifications, including alterations in microRNA (miRNA) expression.
View Article and Find Full Text PDFJ Opioid Manag
September 2025
Retired Addiction Physician and Psychiatrist, London SE1, United Kingdom. ORCID: https://orcid.org/0000-0002-5035-5833.
Despite the contribution of the µ-agonist fentanyl to the United States's opiate overdose epidemic, no human studies specifically address the ability of extended-release preparations of the opiate antagonist naltrexone (NTX) to block fentanyl's life-threatening µ-agonist-mediated respiratory depression. This paper presents three case histories of clinically necessary opiate challenges in opiate-abusing patients implanted with extended-release NTX (ER-NTX). It also reviews the sparse literature and is the first evidence that antagonist blood levels from ER-NTX preparations can completely block the lethal µ-agonist effects of at least 1,000 mcg of intravenous fentanyl.
View Article and Find Full Text PDF